Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of TELOMIR-1, a novel small molecule designed to lengthen the DNA’s protective telomere caps, thereby promoting longevity in humans and canine animals by treating age-related conditions. TELOMIR-1 is undergoing studies to provide a therapeutic intervention against contracting a number of degenerative and age-related diseases. Its Telomir-1, is being investigated for its potential to address a range of conditions, including Type 2 diabetes, Wilson’s disease, progeria, Alzheimer’s disease, and cancer. The Company is focused on developing and commercializing TELOMIR-1, proposed to be dosed orally, with the aim of promoting longevity and enhancing overall quality of life. It is being developed to protect stem cells by elongating and stimulating the telomeres to sustain self-renewal.
Ticker SymbolTELO
Company nameTelomir Pharmaceuticals Inc
IPO dateFeb 09, 2024
CEOMr. Erez Aminov
Number of employees- -
Security typeOrdinary Share
Fiscal year-endFeb 09
Address900 West Platt Street, Suite 200
CityTAMPA
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code33606
Phone18138642562
Websitehttps://telomirpharma.com/
Ticker SymbolTELO
IPO dateFeb 09, 2024
CEOMr. Erez Aminov
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data